<?xml version="1.0" encoding="UTF-8"?>
<p>The proportion of reported symptoms was estimated at 25.5% (95% CI, 20.3%–31.4%) in ZIKV-positive participants vs 3.6% (95% CI, 2.6%–5.0%) in seronegative individuals, resulting in a ZIKV-attributable symptomatic infection rate of 21.9%.</p>
